We conducted a population-based, case-control study to determine whether β-blockers, used for the treatment of hypertension, prevent first events of coronary heart disease. Cases were patients who had high blood pressure treated with medicines and who presented in 1982 to 1984 with angina or fatal or nonfatal myocardial infarction. Controls were a probability sample of health maintenance organization patients with pharmacologically treated hypertension and free of coronary heart disease. Blinded to case-control status, we reviewed the medical records of the 248 cases and 737 controls. The health maintenance organization's computerized pharmacy database was used to ascertain the use of β-blockers. Fewer cases than controls were taking β-blockers. This difference was confined to those with nonfatal infarctions. After adjustment for confounding, the estimated relative risk was 0.62 (95% confidence interval, 0.39 to 0.99). Higher doses of β-blockers conferred greater protection. We conclude that β-blockers may prevent first events of nonfatal myocardial infarction in patients with high blood pressure.
Psaty BM, Koepsell TD, LoGerfo JP, Wagner EH, Inui TS. β-Blockers and Primary Prevention of Coronary Heart Disease in Patients With High Blood Pressure. JAMA. 1989;261(14):2087–2094. doi:10.1001/jama.1989.03420140089033
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: